Expert Interview
Discussing Vanda Pharmaceuticals' FDA Approval of BYSANTI™ (Milsaperidone) for Bipolar I Disorder and Schizophrenia
Ticker(s): VNDA, OTSKY, LLY, JNJ, AZN, PFE, ABBV, ITCI, BMYInstitution: Columbia University/ NewYork-Presbyterian Hospital
- Professor and Former Chairman of Psychiatry at Columbia University; Former President of the American Psychiatric Association & former Director of the New York State Psychiatric Institute.
- Currently manages 88 patients with bipolar I disorder or schizophrenia
- Internationally recognized leader in psychiatry specializing in schizophrenia and psychotic disorders; Principal Investigator of landmark NIH-funded studies including CATIE and RAISE and key contributor to national treatment guidelines and psychiatric research policy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
